A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection

BMC Infectious Diseases

Volumn 9, Issue , 2009, Pages

  Morris, Shaun K ^a   Dzolganovski, Biljana ^a   Beyene, Joseph ^a   Sung, Lillian ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB; PLACEBO; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; ANTIVIRUS AGENT; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS IMMUNE GLOBULIN INTRAVENOUS;

ARTICLE; ARTIFICIAL VENTILATION; CHRONIC LUNG DISEASE; CONGENITAL HEART DISEASE; CONGENITAL HEART MALFORMATION; CYANOSIS; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EFFICACY; FEVER; GESTATIONAL AGE; HOSPITALIZATION; HUMAN; INCIDENCE; INFECTION RISK; INTENSIVE CARE UNIT; META ANALYSIS; MORTALITY; OXYGEN SATURATION; PROPHYLAXIS; RESPIRATORY DISTRESS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RISK REDUCTION; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; INFANT; RISK FACTOR; STATISTICS; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; HOSPITALIZATION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT; RESPIRATION, ARTIFICIAL; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RISK FACTORS; TREATMENT OUTCOME;

EID: 68949194356     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-9-106     Document Type: Article

References (21)

1. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986, 140(6):543-6.
2. Wang EE, Law BJ, Stephens D. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr 1995, 126(2):212-9. 10.1016/S0022-3476(95)70547-3, 7844667.
3. Navas L, Wang E, de Carvalho V, Robinson J. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada. J Pediatr 1992, 121(3):348-54. 10.1016/S0022-3476(05)90000-0, 1517907.
4. Wang EE, Tang NK. Immunoglobulin for preventing respiratory syncytial virus infection. Cochrane Database Syst Rev 2000, 2:CD001725.
5. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999, 354(9193):1896-900. 10.1016/S0140-6736(99)04149-5, 10584742.
6. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977, 33(1):159-74. 10.2307/2529310, 843571.
7. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17(1):1-12. 10.1016/0197-2456(95)00134-4, 8721797.
8. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7(3):177-88. 10.1016/0197-2456(86)90046-2, 3802833.
9. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003, 327(7414):557-60. 192859, 12958120, 10.1136/bmj.327.7414.557.
10. Sutton AJ, Duval SJ, Tweedie RL, Abrams KR, Jones DR. Empirical assessment of effect of publication bias on meta-analyses. BMJ 2000, 320(7249):1574-7. 27401, 10845965, 10.1136/bmj.320.7249.1574.
11. Groothuis JR, Simoes EA, Levin MJ, Hall CB, Long CE, Rodriguez WJ, Arrobio J, Meissner HC, Fulton DR, Welliver RC, Tristram DA, Siber GR, Prince GA, Raden MV, Hemming VG, . for The Respiratory Syncytial Virus Immune Globulin Study Group Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med 1993, 329(21):1524-30. 10.1056/NEJM199311183292102, 8413475, for The Respiratory Syncytial Virus Immune Globulin Study Group.
12. The Prevent Study Group Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 1997, 99(1):93-9. 10.1542/peds.99.1.93, 8989345, The Prevent Study Group.
13. Simoes EA, Sondheimer HM, Top FH, Meissner HC, Welliver RC, Kramer AA, Groothuis JR. Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group. J Pediatr 1998, 133(4):492-9. 10.1016/S0022-3476(98)70056-3, 9787686.
14. Subramanian KN, Weisman LE, Rhodes T, Ariagno R, Sánchez PJ, Steichen J, Givner LB, Jennings TL, Top FH, Carlin D, Connor E. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatr Infect Dis J 1998, 17(2):110-5. 10.1097/00006454-199802000-00006, 9493805.
15. The IMpact-RSV Study Group Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998, 102(3 Pt 1):531-7. The IMpact-RSV Study Group.
16. Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH, Connor EM, Sondheimer HM, . Cardiac Synagis Study Group Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003, 143(4):532-40. 10.1067/S0022-3476(03)00454-2, 14571236, Cardiac Synagis Study Group.
17. MedImmune. Synagis RSV protection medication for high-risk babies' lungs. MedImmune. Synagis., http://www.synagis.com
18. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003, 112(6 Pt 1):1442-6. 10.1542/peds.112.6.1442, 14654627, American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn.
19. Infectious Diseases and Immunization Committee, Canadian Paediatric Society (CPS) Use of Palivizumab in Children with Congenital Heart Disease. Paediatrics & Child Health 2003, 8(10):632-633. Infectious Diseases and Immunization Committee, Canadian Paediatric Society (CPS).
20. Wu H, Pfarr DS, Johnson S, Brewah YA, Woods RM, Patel NK, White WI, Young JF, Kiener PA. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol 2007, 368(3):652-65. 10.1016/j.jmb.2007.02.024, 17362988.
21. Carbonell X, Genevieve L, Micki H, Edward C, . the Motavizumab Study Group Phase 3 Trial of Motavizumab (MEDI-524), an Enhanced Potency Respiratory Syncytial Virus (RSV) Specific Monoclonal Antibody (Mab) for the Prevention of Serious RSV Disease in High Risk Infants. Poster presented at: Pediatric Academic Societies Annual Meeting, May 8, 2007; Toronto, ON the Motavizumab Study Group.